CNSX:PMC

Pharmerica Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume13,000 shs

Average Volume5,703 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive PMC News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmerica and its competitors with MarketBeat's FREE daily newsletter.

About Pharmerica

Peloton Minerals Corporation, a mineral exploration company, acquires and explores for mineral properties in Canada and the United States. The company primarily explores for gold and silver deposits. It principally owns three gold exploration projects located in Elko County, Nevada; and one gold exploration project in Montana, the United States. The company was formerly known as Montana Gold Mining Company Inc. and changed its name to Peloton Minerals Corporation in 2016. Peloton Minerals Corporation was incorporated in 2000 and is headquartered in London, Canada.

A dummies guide to the world of wines
October 11, 2020 | msn.com

$5B United States Esters Market: Size, Share & Trends Analysis Report, 2019-2025
December 15, 2019 | www.benzinga.com

Indian police probe management of co-operative bank
October 2, 2019 | sg.finance.yahoo.com

African Metals Corporation and Frederick Private Equity Corporation Sign Agreement on the Silver Bell - St. Lawrence Gold Project, Montana
April 26, 2019 | www.baystreet.ca

Phoenix Guarantor Inc. -- Moody's announces completion of a periodic review of ratings of Phoenix Guarantor Inc.
March 21, 2019 | finance.yahoo.com

Phoenix Guarantor Inc. -- Moody's: Phoenix Guarantor's bolt-on acquisition raises integration risk - ratings unaffected
February 13, 2019 | finance.yahoo.com

Phoenix Guarantor Inc. -- Moody's assigns B2 CFR to Phoenix Guarantor Inc., outlook stable
January 28, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: CNSX
Industry: Gold
Sub-Industry: N/A
Sector: Basic Materials
Current Symbol: CNSX:PMC
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.pharmerica.com
Phone: 519-964-2836
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.93 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Pharmerica.

4.7 Community Rank

Outperform Votes
Pharmerica has received 30 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Pharmerica has received 13 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Pharmerica has received 69.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Pharmerica and other stocks. Vote “Outperform” if you believe PMC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PMC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Pharmerica does not currently pay a dividend.
Dividend Growth
Pharmerica does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pharmerica insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Pharmerica (CNSX:PMC) Frequently Asked Questions

What stocks does MarketBeat like better than Pharmerica?: Wall Street analysts have given Pharmerica a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pharmerica wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Pharmerica's key executives?: Pharmerica's management team includes the following people:
Mr. Edward L. Ellwood M.B.A., MBA, Pres, CEO & Director (Age 61, Pay $120k)
Mr. Eric J. Plexman, Corp. Sec., CFO & Director (Age 68, Pay $65k)
Mr. Richard Crissman Capps Ph.D., Independent Sr. Geologist & Director
Mr. Paul V. Teodorovici, Exec. VP & Director
Mr. Paul Strobel, VP of Marketing & Bus. Devel. (Age 74)
Who are some of Pharmerica's key competitors?: Some companies that are related to Pharmerica include Aben Resources (ABNAF), African Gold Group (AGGFF), AIC Mines (A1M), Alacer Gold (ALIAF), ALACERGOLD/IDR UNRESTR (AQG), Alchemy Resources (ALY), Alliance Resources (AGS), Amani Gold (ANL), Amex Exploration (AMXEF), Anaconda Mining (ANXGF), Anglo Australian Resources (AAR), AngloGold Ashanti (AGG), Anova Metals (AWV), Apollo Consolidated (AOP) and Argo Gold (ARQ).
View all of PMC's competitors.
What other stocks do shareholders of Pharmerica own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmerica investors own include Enbridge (ENB), Delta Air Lines (DAL), Air Canada (AC), TELUS (T), Fortis (FTS), Ford Motor (F), Enterprise Products Partners (EPD), Capital Power (CPX), Bank of America (BAC) and The Boeing (BA).
What is Pharmerica's stock symbol?: Pharmerica trades on the CNSX under the ticker symbol "PMC."
How do I buy shares of Pharmerica?: Shares of PMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pharmerica's official website?: The official website for Pharmerica is www.pharmerica.com.
How can I contact Pharmerica?: The company can be reached via phone at 519-964-2836.

This page was last updated on 10/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.